NexgenRx Inc. Stock

NXG

CA65337X1042

Investment Management & Fund Operators

Market Closed - Toronto S.E. Other stock markets 14:12:55 2026-07-17 EDT			5-day change	1st Jan Change
0.5500 ^CAD	+5.77%		+14.58%	+37.50%

05-22	Earnings Flash (NXG.V) NexgenRx Reported Q1 Total Revs $5.0M, Up 11.6% YoY; Net Income and EBITDA Improved	MT
05-21	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

NexgenRx Inc. is a Canada-based independent full-service third-party administrator and technology solutions provider. The Company administers, adjudicates and pays drug, dental and other extended healthcare claims for the beneficiaries of health benefit plans underwritten by its customers, using proprietary computer software and also providing ancillary services. It offers plan sponsors, providers and patient support program/drug manufacturers a full suite of software-as-a-service solutions. The Companyâ€™s products include NexSys, NexAdmin, and NexPSPAssist. The NexSys is a fully integrated rules based adjudication platform for secure real-time processing of drug, dental and extended health benefit claims. Its NexAdmin product enables sponsors to take complete control of benefit plan administration. The NexPSPAssist service helps patient support programs (PSP) to optimize their deliverables to their manufacturer clients.

Employees

Sector

Investment Management & Fund Operators

More about the company

Quotes

Date	Price	Change	Volume
26-07-17	$0.5500	+5.77%	8,500
26-07-15	$0.5200	0.00%	8,029
26-07-13	$0.5200	+8.33%	51,001

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	39.11M 27.92M 24.4M 22.51M 20.75M 2.69B 39.98M 269M 106M 1.32B 105M 103M 4.53B	P/E 2024	55x	P/E 2025	28.6x
Enterprise Value	34.7M 24.77M 21.65M 19.98M 18.41M 2.39B 35.47M 239M 93.91M 1.17B 93.03M 90.98M 4.02B	EV / Sales 2024	1.12x	EV / Sales 2025	1.34x
Free-Float	63.03%	Yield 2024	3.64%	Yield 2025	3.75%

05-22	Earnings Flash (NXG.V) NexgenRx Reported Q1 Total Revs $5.0M, Up 11.6% YoY; Net Income and EBITDA Improved	MT
05-21	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-19	NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026	CI
03-31	NexgenRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-10	NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025	CI
11-21	NexgenRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-21	NexgenRx Q3 Revenue Rises 13%, Net Income and EBITDA Improve	MT
11-20	Earnings Flash (NXG.V) NexgenRx Reported Q3 Revenue $4.6M	MT
25-08-18	NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025	CI
25-08-12	NexgenRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	NexgenRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-17	Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025	CI
24-11-25	Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024	CI

1 day	+5.77%
1 week	+14.58%
Current month	+19.57%
1 month	+26.44%
3 months	+41.03%
6 months	+52.78%
Current year	+37.50%

1 week	0.48	0.56
1 month	0.44	0.56
Current year	0.29	0.56
1 year	0.29	0.56
3 years	0.18	0.56
5 years	0.18	0.56
10 years	0.14	0.6

Manager	Title	Age	Since
Ronald Loucks CEO	Chief Executive Officer	-	2003-03-12
Phoebe Lee DFI	Director of Finance/CFO	-	-
Kelly Elher DFI	Director of Finance/CFO	63	2016-12-04

NexgenRx Inc. Stock

Stocks

NXG

CA65337X1042

Investment Management & Fund Operators

Valuation: NexgenRx Inc.

Chart: NexgenRx Inc.

Latest news : NexgenRx Inc.

Quotes and Performance

Course Extremes

Managers and Directors: NexgenRx Inc.

Latest insider transactions

Other Investment Management & Fund Operators

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Ronald Loucks BRD	Director/Board Member	-	2003-03-12
Thomas Corcoran CHM	Chairman	-	2006-03-06
Charles Burns BRD	Director/Board Member	-	2017-06-15

Date	Insider	Type	Quantity	% Market Cap.
10/1/24	Paul Everett Crossett	Buy	14,500	0.0204%
9/17/24	Paul Everett Crossett	Buy	20,000	0.0281%
9/13/24	Paul Everett Crossett	Buy	15,000	0.0211%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEXGENRX INC.	+5.77%	+14.58%	+42.86%	+83.33%	27.92M
BLACKROCK, INC.	-1.37%	+3.48%	-3.00%	+47.31%	166B
UBS GROUP AG	-1.89%	+1.14%	+47.45%	+134.64%	164B
BANK OF NEW YORK MELLON CORPORATION (THE)	-2.32%	+3.43%	+60.47%	+260.89%	107B
BROOKFIELD CORPORATION	-1.72%	-1.31%	-2.04%	+103.27%	97.52B
BROOKFIELD ASSET MANAGEMENT LTD.	-2.72%	+2.28%	-19.89%	+56.30%	77.17B
STATE STREET CORPORATION	-1.70%	+1.27%	+69.80%	+174.39%	50.51B
AMERIPRISE FINANCIAL, INC.	-1.00%	+4.17%	-2.21%	+53.90%	47.45B
3I GROUP PLC	-2.53%	-4.73%	-39.30%	+33.68%	34.84B
NORTHERN TRUST CORPORATION	-2.04%	+0.62%	+45.35%	+162.07%	34.17B
Average	-1.15%	+1.61%	+19.95%	+110.98%	77.82B
Weighted average by Cap.	-1.87%	+2.23%	+20.03%	+115.92%

	2024	2025
Net sales	16.48M 11.76M 10.28M 9.48M 8.74M 1.13B 16.84M 113M 44.58M 555M 44.16M 43.19M 1.91B	17.93M 12.8M 11.19M 10.32M 9.51M 1.23B 18.33M 123M 48.53M 604M 48.07M 47.01M 2.08B
Net income	615K 439K 383K 354K 326K 42.24M 628K 4.23M 1.66M 20.69M 1.65M 1.61M 71.22M	1.29M 921K 804K 742K 684K 88.65M 1.32M 8.87M 3.49M 43.42M 3.46M 3.38M 149M
Net Debt	-1.17M -836K -731K -674K -622K -80.55M -1.2M -8.06M -3.17M -39.45M -3.14M -3.07M -136M	-4.41M -3.15M -2.75M -2.54M -2.34M -303M -4.51M -30.35M -11.94M -148M -11.82M -11.56M -511M